{"url_path":"/sec/inab/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1740279/0001193125-26-249684-index.html","accession_number":"0001193125-26-249684","cik":"0001740279","ticker":"INAB","issuer_name":"IN8BIO, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1740279/0001193125-26-249684-index.html","primary_entity_key":"0001740279","primary_entity_name":"IN8BIO, INC."},"word_count":116,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNo.\n\n  \n\nDescription\n\n 5.1\n  \n[Opinion of Cooley LLP, dated June 1, 2026.](d100941dex51.htm)\n\n10.1\n  \n[Capital on DemandTM Sales Agreement, dated as of June 1, 2026, by and between IN8bio, Inc. and JonesTrading Institutional Services LLC.](d100941dex101.htm)\n\n23.1\n  \n[Consent of Cooley LLP (included in Exhibit 5.1).](d100941dex51.htm)\n\n101\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \nIN8bio, Inc.\n\nDate: June 1, 2026\n \n\n \nBy:\n \n\n/s/ Patrick McCall\n\n \n\n \n\n \nPatrick McCall\n\n \n\n \n\n \n\nChief Financial Officer and Secretary\n\n(Principal Financial and Accounting Officer)"}